Evidence map›Paper›PMID 36052060›Full record

ArticleFrontiers in immunology2022

High baseline expression of IL-6 and IL-10 decreased CCR7 B cells in individuals with previous SARS-CoV-2 infection during BNT162b2 vaccination.

Alberto Ponciano-Gómez, Martha Iris Valle-Solis, Myriam Campos-Aguilar, Rafael Jijón-Lorenzo, Elena de la C Herrera-Cogco, Roberto Ramos-Alor, César Isaac Bazán-Mendez, Gustavo Antonio Pérez-Gil Cervantes, Ricardo Ávila-García, Abdiel González Aguilar and 14 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 6 institutions in 1 country.

Alberto Ponciano-GómezLaboratorio de Inmunología, Unidad de Morfología y Función, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, Estado de México, Mexico.
Martha Iris Valle-SolisSecretaría de Salud de Veracruz, Servicios de Salud de Veracruz, SESVER, Xalapa Veracruz, Mexico.
Myriam Campos-AguilarLaboratorio de Inmunología, Unidad de Morfología y Función, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, Estado de México, Mexico.
Rafael Jijón-LorenzoSecretaría de Salud de Veracruz, Servicios de Salud de Veracruz, SESVER, Xalapa Veracruz, Mexico.
Elena de la C Herrera-CogcoSecretaría de Salud de Veracruz, Servicios de Salud de Veracruz, SESVER, Xalapa Veracruz, Mexico.
Roberto Ramos-AlorSecretaría de Salud de Veracruz, Servicios de Salud de Veracruz, SESVER, Xalapa Veracruz, Mexico.
César Isaac Bazán-MendezLaboratorio Estatal de Salud Pública, Gobierno del Estado de Veracruz, Veracruz, Mexico.
Gustavo Antonio Pérez-Gil CervantesSecretaría de Salud de Veracruz, Servicios de Salud de Veracruz, SESVER, Xalapa Veracruz, Mexico.
Ricardo Ávila-GarcíaSecretaría de Salud de Veracruz, Servicios de Salud de Veracruz, SESVER, Xalapa Veracruz, Mexico.
Abdiel González AguilarSecretaría de Salud de Veracruz, Servicios de Salud de Veracruz, SESVER, Xalapa Veracruz, Mexico.
Moises Geovani Salmerón TexaleSecretaría de Salud de Veracruz, Servicios de Salud de Veracruz, SESVER, Xalapa Veracruz, Mexico.
Wilfrido David Tapia-SánchezLaboratorio de Citometría de Flujo y Hematología, Diagnóstico Molecular de Leucemias y Terapia Celular (DILETEC), Gustavo A. Madero, Ciudad de Mexico, Mexico.
Carlos Leonardo Duarte-MartínezLaboratorio de Citometría de Flujo y Hematología, Diagnóstico Molecular de Leucemias y Terapia Celular (DILETEC), Gustavo A. Madero, Ciudad de Mexico, Mexico.
Sandra Olivas-QuinteroDepartment of Health Sciences, Autonomus University of Occident, Culiacan, Sinaloa, Mexico.
Santiago Cristobal Sigrist-FloresLaboratorio de Inmunología, Unidad de Morfología y Función, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, Estado de México, Mexico.
Itzell Alejandrina Gallardo-OrtízUnidad de Biomedicina, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, Estado de México, Mexico.
Rafael Villalobos-MolinaUnidad de Biomedicina, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, Estado de México, Mexico.
Adolfo Rene Méndez-CruzLaboratorio de Inmunología, Unidad de Morfología y Función, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, Estado de México, Mexico.
Rafael Jimenez-FloresLaboratorio de Inmunología, Unidad de Morfología y Función, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, Estado de México, Mexico.
Leopoldo Santos-ArgumedoDepartamento de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Ciudad de México, Mexico.
Juan Pedro Luna-AriasDepartamento de Biología Celular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Ciudad de México, Mexico.
Hector Romero-RamírezDepartamento de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Ciudad de México, Mexico.
Victor Hugo Rosales-GarcíaLaboratorio de Citometría de Flujo y Hematología, Diagnóstico Molecular de Leucemias y Terapia Celular (DILETEC), Gustavo A. Madero, Ciudad de Mexico, Mexico.
Bartolo Avendaño-BorromeoSecretaría de Salud de Veracruz, Servicios de Salud de Veracruz, SESVER, Xalapa Veracruz, Mexico.
Secretaria de Salud · MXUniversidad Nacional Autónoma de México · MXCenter for Research and Advanced Studies of the National Polytechnic Institute · MXAutonomous University of Tlaxcala · MXFederal Government of Mexico · MXUniversidad de Occidente · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current pandemic generated by SARS-CoV-2 has led to mass vaccination with different biologics that have shown wide variations among human populations according to the origin and formulation of the vaccine. Studies evaluating the response in individuals with a natural infection before vaccination have been limited to antibody titer analysis and evaluating a few humoral and cellular response markers, showing a more rapid and intense humoral response than individuals without prior infection. However, the basis of these differences has not been explored in depth. In the present work, we analyzed a group of pro and anti-inflammatory cytokines, antibody titers, and cell populations in peripheral blood of individuals with previous SARS-CoV-2 infection using BNT162b2 biologic. Our results suggest that higher antibody concentration in individuals with an earlier disease could be generated by higher production of plasma cells to the detriment of the presence of memory B cells in the bloodstream, which could be related to the high baseline expression of cytokines (IL-6 and IL-10) before vaccination.

Indexed as

COVID-19Viral VaccinesBNT162 VaccineHumansInterleukin-10Interleukin-6Receptors, CCR7SARS-CoV-2VaccinationBNT162 VaccineCCR7 protein, humanInterleukin-10Interleukin-6Receptors, CCR7Viral VaccinesBNT162b2CCR7 B cellsInterleukin 10Interleukin 6SARS-CoV-2

Identifiers

PMID36052060
PMCPMC9425053
OpenAlexW4292059691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.